Compare Inovio Pharmaceuticals Inc (INO) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Charles Schwab Corporation Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Charles Schwab Corporation Common Stock trades at $99.35 (market cap $178.33B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 1997.6× Inovio Pharmaceuticals Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.25% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SCHW | |
|---|---|---|
Market Cap | $89.27M | $178.33B |
Sector | Health | Financials |
52-Week High | $2.87 | $107.21 |
52-Week Low | $1.05 | $85.35 |
Enterprise Value | $60.28M | — |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Charles Schwab (SCHW) trades at $102.01, up 0.44% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $1.43 and revenue growth accelerating to $23.92 billion in 2025. Analyst sentiment remains positive with 58% buy ratings and a $120 consensus price target representing 18% upside potential. Recent news highlights strong trading activity and earnings optimism ahead of Q2 results.
The outlook remains favorable with earnings momentum and operational strength driving potential upside. Key opportunities include continued trading revenue growth and margin expansion, while risks involve interest rate sensitivity and market volatility. The stock's current valuation at 20.19 P/E appears reasonable given the company's profitability and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
